Amryt Pharma Valuation
Is AMYT undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 5/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for AMYT?
Other financial metrics that can be useful for relative valuation.
|What is AMYT's n/a Ratio?|
Price to Sales Ratio vs Peers
How does AMYT's PS Ratio compare to its peers?
|AMYT PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
ESPR Esperion Therapeutics
FULC Fulcrum Therapeutics
OCUL Ocular Therapeutix
CARA Cara Therapeutics
AMYT Amryt Pharma
Price-To-Sales vs Peers: AMYT is good value based on its Price-To-Sales Ratio (1.9x) compared to the peer average (13.2x).
Price to Earnings Ratio vs Industry
How does AMYT's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?
Price-To-Sales vs Industry: AMYT is good value based on its Price-To-Sales Ratio (1.9x) compared to the US Pharmaceuticals industry average (2.8x)
Price to Sales Ratio vs Fair Ratio
What is AMYT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||1.9x|
|Fair PS Ratio||3.5x|
Price-To-Sales vs Fair Ratio: AMYT is good value based on its Price-To-Sales Ratio (1.9x) compared to the estimated Fair Price-To-Sales Ratio (3.5x).
Share Price vs Fair Value
What is the Fair Price of AMYT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: AMYT ($7.1) is trading below our estimate of fair value ($109.61)
Significantly Below Fair Value: AMYT is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.